Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pacific Edge Limited ( (PFGTF) ) has provided an announcement.
Pacific Edge Limited reported steady Cxbladder test volumes for the third quarter of FY25, despite challenges posed by Medicare uncertainties and a seasonal holiday slowdown. The company saw a slight increase in total laboratory throughput, particularly in the US, and highlighted efforts to enhance demand from supportive clinicians. Additionally, Pacific Edge emphasized its strategic advances, including engaging with the BlueCross Blue Shield network for non-Medicare revenue and addressing finalized Local Coverage Determination challenges to secure reimbursement stability.
More about Pacific Edge Limited
Pacific Edge Limited is a global leader in cancer diagnostics, specializing in bladder cancer diagnostic and prognostic tests. Based in Dunedin, New Zealand, the company offers its Cxbladder test suite globally through CLIA certified laboratories in New Zealand and the USA.
YTD Price Performance: -49.30%
Average Trading Volume: 12,160
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $27.02M
For a thorough assessment of PFGTF stock, go to TipRanks’ Stock Analysis page.
